← Evidence map

ArticleClinical and molecular hepatology2024

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients".

Hae Lim Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients". | OpenQuestion